Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke
NCT ID: NCT03735277
Last Updated: 2020-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2021-03-06
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, open-label, single-center, exploratory clinical study in subjects ≥ 18 years of age who have sustained a recent ischemic stroke. A total of 10 subjects will be enrolled. Subjects will be given a series of baseline neurological assessments, blood tests, and MRI.
All subjects will be administered only ABO- and Rh-matched units of HPC, Cord Blood. Subjects will not be matched for human leukocyte antigen (HLA)-typing. For each administration of HPC, cord blood, the total dose (2.5 × 10\^7 cells/kg; 150 × 10\^7 cells) will be split for intrathecal injection followed immediately by intravenous infusion. HPC, Cord Blood will be administered via intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke within the past 9 days. Intravenous infusion in conjunction with mannitol will be used in instances where a subject is unable to tolerate intrathecal administration. Treatment period consisting of 3 sessions, timed 5 to 12 days apart. Subjects will be monitored for 6 hours post-infusion, and follow up will occur 24 hours after each therapy session. Follow-up phone calls for adverse event (AE) assessment will be conducted at 1 week, 1 month, and 2 months after the first intravenous/intrathecal treatment. A follow up clinic visit at 2 weeks, 3 months, 6 months, and 12 months after the first intravenous/intrathecal treatment will include a neurological exam, MRI, and clinical laboratory tests/urinalysis.
Risks of cord blood infusion include infusion-related reactions such as anaphylaxis, urticaria, dyspnea, hypoxia, cough, wheezing, bronchospasm, nausea, vomiting, hives, fever, hypertension, hypotension, bradycardia, tachycardia, rigors, chills, infection, and hemoglobinuria. Less likely, long-term risks include transmission of infection or Graft vs Host Disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HPC, Cord Blood
HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters.
HPC, Cord Blood
HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HPC, Cord Blood
HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is ≥ 18 years old
* Has had a recent (within the past 9 days), acute, cortical, hemispheric, ischemic stroke in the MCA distribution without a midline shift as detected by MRI as a diffusion-weighted image (DWI) abnormality
* Has a persistent neurological deficit (NIHSS ≥ 7) at the time of enrollment with no more than a 4-point increase (worsening of score) from the screening baseline score compared to NIHSS baseline score at 24 hours prior to infusion.
* A platelet count \> 100,000/µL, hemoglobin \> 8 g/dL, and white blood cell count (WBC) \> 2500/µL
* Subjects who received tPA or underwent mechanical reperfusion may be included in the study
* Is able to provide consent to study or consent is obtained from the subject's legally authorized representative
* Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the investigator, they will not become pregnant during the course of the study
* Is a good candidate for the study, in the opinion of the investigator
* Agrees to participate in follow-up visits
Exclusion Criteria
Medical Conditions
* Has a medical history of neurological or orthopedic pathology with a deficit as a consequence that results in an mRS \> 1 before stroke or has a pre-existing cognitive deficit
* Has clinically significant and/or symptomatic hemorrhage associated with stroke
* Has new intracranial hemorrhage, edema, or mass effect that may place the subject at increased risk for secondary deterioration when assessed prior to infusion
* Has hypotension as defined as the need for intravenous pressor support of systolic blood pressure \< 90 mm Hg
* Has isolated brain stem stroke
* Has pure lacunar stroke
* Requires mechanical ventilation
* Requires a craniotomy
* Has a serious psychiatric or neurological disease that could alter evaluation on functional or cognitive scales
* Has an active systemic infection or is human immunodeficiency virus (HIV) positive or hepatitis C positive
* Has had an active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma
* Has known coagulopathy such as Factor V Leyden, antiphospholipid syndrome (APS), Protein C, Protein S deficiency, sickle cell, anticardiolipin antibody, or phospholipid syndrome
* Has any concurrent illness or condition that in the opinion of the investigator might interfere with treatment or evaluation of safety
* Has a life expectancy \< 6 months
* Has current or recent history of alcohol or drug abuse, or stroke associated with drug abuse
* Pregnant as documented by urine or blood test
* Renal insufficiency with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2
* Hepatic insufficiency (bilirubin \> 2.5 mg/dL or transaminases \> 3 × the upper limit of normal). Subjects with Gilbert's syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level
* Uncontrolled or poorly controlled type 1 or type 2 diabetes with HbA1c \> 7%
* Has a history of impaired hemostasis or has a prothrombin time \> 14 seconds/international normalized ratio (INR) \> 1.3 second and activated partial thromboplastin time (aPTT) of \> 70 seconds.
* Has a severe persistent neurological deficit (NIHSS \> 24) at the time of enrollment or 24 hours prior to infusion.
* Has New York Heart Association Class III or IV congestive heart failure.
Concomitant or Prior Therapies
* Subjects currently receiving immunosuppressant drugs
* Clinical signs and symptoms of infection requiring antibiotic therapy at the time of enrollment that prevent adequate completion of study-related assessments as judged by the investigator
* Current therapy with anabolic steroids or appetite stimulants
* History of prior transfusion reaction
* History of intolerance or allergic response to similar biological products
* Known sensitivity to dimethyl sulfoxide (DMSO), Dextran 40, or plasma proteins
* Currently on dialysis
* Recipient of bone marrow or organ transplant
* Any previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy
* Subjects participating in another interventional clinical study of an investigational therapy within 30 days of screening
Other
* Lactating women
* Unable to be evaluated for follow-up visits
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BHI Therapeutic Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brian Mehling
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Mehling, MD
Role: PRINCIPAL_INVESTIGATOR
BHI Therapeutic Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BHI Therapeutic Sciences
Hackensack, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Brian Mehling, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BHI17-IS-A
Identifier Type: -
Identifier Source: org_study_id